Abstract
Background: The presence of neuropatic pain (NeP) is common in subjects with established Rheumatoid Arthritis (RA), and it can influence the disease remission. These aspects have not been investigated in patients with Early Rheumatoid Arthritis (ERA).
Objective: To investigate the effect of NeP on the achievement of remission in patients with ERA.
Method: The study involved consecutive ERA patients with moderate or high disease activity. The painDETECT Questionnaire (PDQ), the 36-item Short Form Health Survey (SF-36), and the Euro- QoL-5 Dimensions (EQ-5D) were administered to all the patients, and their co-morbidity data were used to calculate their modified Rheumatic Disease Comorbidity Index (mRDCI). After six months’ follow-up, the presence or otherwise of NeP in each individual patient was calculated, and whether or not the Boolean remission criteria were satisfied.
Results: The study was completed by 115 patients (76% females) whose PDQ scores indicated that 13% had probable NeP. At the end of the follow-up period, 25 patients (21.7%) met the Boolean remission criteria. Logistic regression analysis showed that baseline PDQ scores (p=0.0023) and the mRDCI (p=0.0054) were the strongest predictors of not being in Boolean remission. Only one of the 15 patients with concomitant NeP achieved Boolean remission.
Conclusion: The presence of NeP may affect the achievement of remission in ERA patients. The PDQ can be a useful tool to measure central pain sensitisation in such patients.
Keywords: Early rheumatoid arthritis, neuropathic pain, painDETECT questionnaire, remission, co-morbidities, outcome measures.
[1]
Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: Results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23(6): 819-28.
[2]
Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370(9602): 1861-74.
[3]
Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010; 69(4): 631-7.
[4]
Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009; 60(5): 1242-9.
[5]
Lee YC, Cui J, Lu B, et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: A longitudinal observational study. Arthritis Res Ther 2011; 13(3): R83.
[6]
Wolfe F, Boers M, Felson D, Michaud K, Wells GA. Remission in rheumatoid arthritis: Physician and patient perspectives. J Rheumatol 2009; 36(5): 930-3.
[7]
Hochman JR, Gagliese L, Davis AM, Hawker GA. Neuropathic pain symptoms in a community knee OA cohort. Osteoarthritis Cartilage 2011; 19(6): 647-54.
[8]
Amris K, Jespersen A, Bliddal H. Self-reported somatosensory symptoms of neuropathic pain in fibromyalgia and chronic widespread pain correlate with tender point count and pressure-pain thresholds. Pain 2010; 151(3): 664-9.
[9]
Wu Q, Inman RD, Davis KD. Neuropathic pain in ankylosing spondylitis: A psychophysics and brain imaging study. Arthritis Rheum 2013; 65(6): 1494-503.
[10]
Giordano J, Abramson K, Boswell MV. Pain assessment: Subjectivity, objectivity, and the use of neurotechnology. Pain Physician 2010; 13(4): 305-15.
[11]
Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: the saga of clinical tools. Pain 2011; 152(3)(Suppl.): S74-83.
[12]
Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22(10): 1911-20.
[13]
Moreton BJ, Tew V. das Nair R, Wheeler M, Walsh DA, Lincoln NB. Pain phenotype in patients with knee osteoarthritis: Classification and measurement properties of painDETECT and self-report Leeds assessment of neuropathic symptoms and signs scale in a cross-sectional study. Arthritis Care Res (Hoboken) 2015; 67(4): 519-28.
[14]
Christensen AW, Rifbjerg-Madsen S, Christensen R, et al. Non-nociceptive pain in rheumatoid arthritis is frequent and affects disease activity estimation: cross-sectional data from the FRAME study. Scand J Rheumatol 2016; 45(6): 461-9.
[15]
Koop SM, ten Klooster PM, Vonkeman HE, Steunebrink LM, van de Laar MA. Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis. Arthritis Res Ther 2015; 17: 237.
[16]
Rifbjerg-Madsen S, Christensen AW, Boesen M, et al. Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: Protocol for the Frederiksberg hospital’s Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study. BMJ Open 2014; 4(11): e006058.
[17]
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69(9): 1580-8.
[18]
Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007; 21(4): 663-75.
[19]
Wolfe F, Clauw DJ, Fitzcharles MA, et al. The ACR preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62(5): 600-10.
[20]
Caporali R, Conti F, Covelli M, et al. Treating rheumatoid arthritis to target: an Italian rheumatologists’ survey on the acceptance of the treat-to-target recommendations. Clin Exp Rheumatol 2014; 32(4): 471-6.
[21]
Leeb BF, Andel I, Sautner J, et al. Disease activity measurement of rheumatoid arthritis: Comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. Arthritis Rheum 2005; 53(1): 56-60.
[22]
Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42(2): 244-57.
[23]
Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63(3): 573-86.
[24]
Apolone G, Mosconi P. The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 1998; 51(11): 1025-36.
[25]
Scalone L, Cortesi PA, Ciampichini R, et al. Italian population-based values of EQ-5D health states. Value Health 2013; 16(5): 814-22.
[26]
Spaetgens B, Wijnands JM, van Durme C, Boonen A. Content and construct validity of the Rheumatic Diseases Comorbidity Index in patients with gout. Rheumatology (Oxford) 2015; 54(9): 1659-63.
[27]
Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21(5): 885-906.
[28]
Abrahams MJ. Neuropathic pain in soft tissue complaints. Best Pract Res Clin Rheumatol 2007; 21(2): 223-44.
[29]
Hochman JR, Davis AM, Elkayam J, Gagliese L, Hawker GA. Neuropathic pain symptoms on the modified painDETECT correlate with signs of central sensitization in knee osteoarthritis. Osteoarthritis Cartilage 2013; 21(9): 1236-42.
[30]
Soni A, Batra RN, Gwilym SE, et al. Neuropathic features of joint pain: A community-based study. Arthritis Rheum 2013; 65(7): 1942-9.
[31]
Walsh DA, McWilliams DF. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat Rev Rheumatol 2014; 10(10): 581-92.
[32]
Phillips K, Clauw DJ. Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum 2013; 65(2): 291-302.
[33]
Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118(11): 3537-45.
[34]
Scuri M, Samsell L, Piedimonte G. The role of neurotrophins in inflammation and allergy. Inflamm Allergy Drug Targets 2010; 9(3): 173-80.
[36]
Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70(18): 1630-5.
[37]
Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain 2007; 127(3): 199-203.
[38]
Gwilym SE, Keltner JR, Warnaby CE, et al. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum 2009; 61(9): 1226-34.
[39]
Garip Y, Eser F, Kilicarslan A, Bodur H. Prevalence of neuropathic pain in rheumatic disorders: Association with disease activity, functional status and quality of life. Arch Rheumatolo 2015; 30(X): i-vii.
[40]
Meirinhos T, Aguiar R, Ambrósio C, Barcelos A. Neuropathic pain in rheumatic diseases: A cross sectional study. Ann Rheum Dis 2014; 73(Suppl. 1): A76.
[41]
Rifbjerg-Madsen S, Christensen AW, Christensen R, et al. Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey. PLoS One 2017; 12(7): e0180014.
[42]
Fischer BD, Adeyemo A, O’Leary ME, Bottaro A. Animal models of rheumatoid pain: experimental systems and insights. Arthritis Res Ther 2017; 19(1): 146.
[43]
Borenstein D, Altman R, Bello A, et al. Report of the american college of rheumatology pain management task force. Arthritis Care Res (Hoboken) 2010; 62(5): 590-9.
[44]
McWilliams DF, Zhang W, Mansell JS, Kiely PD, Young A, Walsh DA. Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study. Arthritis Care Res (Hoboken) 2012; 64(10): 1505-13.
[45]
Rifbjerg-Madsen S, Christensen AW, Boesen M, et al. The course of pain hypersensitivity according to painDETECT in patients with rheumatoid arthritis initiating treatment: results from the prospective FRAME-cohort study. Arthritis Res Ther 2018; 20(1): 105.
[46]
Vastesaeger N, Kutzbach AG, Amital H, et al. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Rheumatology (Oxford) 2016; 55(8): 1466-76.
[47]
Ranganath VK, Maranian P, Elashoff DA, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford) 2013; 52(10): 1809-17.
[48]
Radner H, Yoshida K, Frits M, et al. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2015; 54(11): 2076-84.
[49]
Iannone F, Salaffi F, Fornaro M, et al. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings. Eur J Clin Invest 2018; 48(11): e13013.
[50]
Ito S, Kobayashi D, Murasawa A, Narita I, Nakazono K. An Analysis of the Neuropathic Pain Components in Rheumatoid Arthritis Patients. Intern Med 2018; 57(4): 479-85.
Related Books
Natural Products for the Management of Arthritic Disorders
Article Metrics
61
2